Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE) (P13-12.007)

Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE) (P13-12.007)

Abstract only

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2023-04, Vol.100 (17_supplement_2)
Hauptverfasser: Straube, Andreas, Brössner, Gregor, Gaul, Charly, Hamann, Xenia, Hipp, Joachim, Kraya, Torsten, Schauerte, Isabel, Neeb, Lars
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 17_supplement_2
container_start_page
container_title Neurology
container_volume 100
creator Straube, Andreas
Brössner, Gregor
Gaul, Charly
Hamann, Xenia
Hipp, Joachim
Kraya, Torsten
Schauerte, Isabel
Neeb, Lars
description Abstract only
doi_str_mv 10.1212/WNL.0000000000203641
format Article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1212_WNL_0000000000203641</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1212_WNL_0000000000203641</sourcerecordid><originalsourceid>FETCH-crossref_primary_10_1212_WNL_00000000002036413</originalsourceid><addsrcrecordid>eNqdkE1Lw0AQhhdRMH78Aw9zbA-p2aQm8VhKqoKW0BTqLWzSSbKS7JbdjSH-I_-lWxQPHp3LwPPyDMxLyA31ZtSn_u1u_Tzzfsf3gnBOT4hD7_zQDQP_9ZQ4FsduEEfxObnQ-s3zbBjdO-Rzg6x1d1K1e0iqCkvD31Gg1iArWCnsmMCPvmMFcAEpMxyF0TBw08ALrxXjAmFoJGQWlQ3urSM7WAhpGlTQLQrYMlWj4aIGi2D5sEmPd5qBjTDJ-qJWsj9YgbWj5vpbXz2tkyxLpjBJaeBS3z4XTa_IWcVajdc_-5LMV8l2-eiWSmqtsMoPindMjTn18mMtua0l_1tL8E_tC9Blans</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE) (P13-12.007)</title><source>Journals@Ovid Ovid Autoload</source><source>Alma/SFX Local Collection</source><creator>Straube, Andreas ; Brössner, Gregor ; Gaul, Charly ; Hamann, Xenia ; Hipp, Joachim ; Kraya, Torsten ; Schauerte, Isabel ; Neeb, Lars</creator><creatorcontrib>Straube, Andreas ; Brössner, Gregor ; Gaul, Charly ; Hamann, Xenia ; Hipp, Joachim ; Kraya, Torsten ; Schauerte, Isabel ; Neeb, Lars</creatorcontrib><description>Abstract only</description><identifier>ISSN: 0028-3878</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000203641</identifier><language>eng</language><ispartof>Neurology, 2023-04, Vol.100 (17_supplement_2)</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Straube, Andreas</creatorcontrib><creatorcontrib>Brössner, Gregor</creatorcontrib><creatorcontrib>Gaul, Charly</creatorcontrib><creatorcontrib>Hamann, Xenia</creatorcontrib><creatorcontrib>Hipp, Joachim</creatorcontrib><creatorcontrib>Kraya, Torsten</creatorcontrib><creatorcontrib>Schauerte, Isabel</creatorcontrib><creatorcontrib>Neeb, Lars</creatorcontrib><title>Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE) (P13-12.007)</title><title>Neurology</title><description>Abstract only</description><issn>0028-3878</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqdkE1Lw0AQhhdRMH78Aw9zbA-p2aQm8VhKqoKW0BTqLWzSSbKS7JbdjSH-I_-lWxQPHp3LwPPyDMxLyA31ZtSn_u1u_Tzzfsf3gnBOT4hD7_zQDQP_9ZQ4FsduEEfxObnQ-s3zbBjdO-Rzg6x1d1K1e0iqCkvD31Gg1iArWCnsmMCPvmMFcAEpMxyF0TBw08ALrxXjAmFoJGQWlQ3urSM7WAhpGlTQLQrYMlWj4aIGi2D5sEmPd5qBjTDJ-qJWsj9YgbWj5vpbXz2tkyxLpjBJaeBS3z4XTa_IWcVajdc_-5LMV8l2-eiWSmqtsMoPindMjTn18mMtua0l_1tL8E_tC9Blans</recordid><startdate>20230425</startdate><enddate>20230425</enddate><creator>Straube, Andreas</creator><creator>Brössner, Gregor</creator><creator>Gaul, Charly</creator><creator>Hamann, Xenia</creator><creator>Hipp, Joachim</creator><creator>Kraya, Torsten</creator><creator>Schauerte, Isabel</creator><creator>Neeb, Lars</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20230425</creationdate><title>Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE) (P13-12.007)</title><author>Straube, Andreas ; Brössner, Gregor ; Gaul, Charly ; Hamann, Xenia ; Hipp, Joachim ; Kraya, Torsten ; Schauerte, Isabel ; Neeb, Lars</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-crossref_primary_10_1212_WNL_00000000002036413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Straube, Andreas</creatorcontrib><creatorcontrib>Brössner, Gregor</creatorcontrib><creatorcontrib>Gaul, Charly</creatorcontrib><creatorcontrib>Hamann, Xenia</creatorcontrib><creatorcontrib>Hipp, Joachim</creatorcontrib><creatorcontrib>Kraya, Torsten</creatorcontrib><creatorcontrib>Schauerte, Isabel</creatorcontrib><creatorcontrib>Neeb, Lars</creatorcontrib><collection>CrossRef</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Straube, Andreas</au><au>Brössner, Gregor</au><au>Gaul, Charly</au><au>Hamann, Xenia</au><au>Hipp, Joachim</au><au>Kraya, Torsten</au><au>Schauerte, Isabel</au><au>Neeb, Lars</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE) (P13-12.007)</atitle><jtitle>Neurology</jtitle><date>2023-04-25</date><risdate>2023</risdate><volume>100</volume><issue>17_supplement_2</issue><issn>0028-3878</issn><eissn>1526-632X</eissn><abstract>Abstract only</abstract><doi>10.1212/WNL.0000000000203641</doi></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2023-04, Vol.100 (17_supplement_2)
issn 0028-3878
1526-632X
language eng
recordid cdi_crossref_primary_10_1212_WNL_0000000000203641
source Journals@Ovid Ovid Autoload; Alma/SFX Local Collection
title Real-World Effectiveness of Fremanezumab in Patients with Migraine who Switched From Another mAb Targeting the CGRP Pathway (Subgroup Analysis From FINESSE) (P13-12.007)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T06%3A28%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-World%20Effectiveness%20of%20Fremanezumab%20in%20Patients%20with%20Migraine%20who%20Switched%20From%20Another%20mAb%20Targeting%20the%20CGRP%20Pathway%20(Subgroup%20Analysis%20From%20FINESSE)%20(P13-12.007)&rft.jtitle=Neurology&rft.au=Straube,%20Andreas&rft.date=2023-04-25&rft.volume=100&rft.issue=17_supplement_2&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000203641&rft_dat=%3Ccrossref%3E10_1212_WNL_0000000000203641%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true